



Ovation Science Announces the Formation of an International Medical Dermatology Advisory Board Focused on Cannabis

Key Opinion Leaders to Provide Expertise for Topical Product Development

VANCOUVER, April 23, 2019 /CNW/ - Ovation Science Inc. (CSE: [OVAT](#)) ("Ovation" or the "Company"), a cannabis product development company with a patented skin delivery technology and backed by over twenty years of research and development, today announced it has entered into an exclusive agreement with Skincareguide.com Ltd., a leading international peer-reviewed publisher and an authoritative source of dermatology information for physicians and consumers since 2001, to act as the Company's Medical Dermatology Advisory Board for cannabis formulated products. The objective of the Medical Dermatology Advisory Board is to provide guidance, along with clinical, scientific, research and strategic advice to the Company as it continues to advance its topical and transdermal cannabis product development.

With the Company's Medical Dermatology Advisory Board in place, Ovation will be able to consider dermatology-focused product line expansion following the previous announcement of its anti-aging product line ARLO Beauty. It will allow Ovation to reinforce the science behind its product lines by relying on this international team of outstanding experts in dermatology as well as increasing its R&D into dermatology-focused conditions in order to maintain and support the Company's advantage in the topical cannabis market globally.

"As a company focused on providing science to support our product lines, we are delighted to announce this important addition to Ovation's research and development process," said Terry Howlett, President of Ovation. "The collective knowledge and insight that each distinguished physician on our Medical Dermatology Advisory Board brings is invaluable to us and ultimately the people that use our products. This board is also a great complement to Ovation's team that combined has over 75 years of dermatology, pharmaceutical and drug delivery experience. Our goal is to provide consumers with products that enhance their health and appearance and ultimately their quality of life. We believe this board will be instrumental in guiding this effort through product development and clinical trial initiatives. We look forward to collaborating with them as we develop our effective, safe and unique pipeline of topical and transdermal cannabis products."

Ovation's Medical Dermatology Advisory Board is comprised of physicians who are key opinion leaders within dermatology. They are:

Board Chair: Charles W. Lynde, M.D., FRCPC: Dr. Lynde is an Assistant Professor in the Department of Medicine at the University of Toronto and holds a clinical teaching position at the University Health Network. He is Medical Director of Lynde Dermatology and Lynderm Research. Dr. Lynde has also done research including more than 160 clinical trials in all areas of dermatology including cosmetic therapies. He has served as President of the Canadian Dermatology Association (CDA) and was recently the recipient of the CDA Award of Merit. This award represents leadership and contributions made to the CDA. He has authored and co-authored more than 150 peer reviewed articles and is the Editor of the CDA Bulletin and sits on the editorial boards of several journals and advisory boards of many pharmaceutical companies.

Richard Thomas, MD, FRCPC: After receiving his medical degree in the UK, Dr. Thomas became an established clinical dermatologist in Vancouver, Canada, and Clinical Assistant Professor at the University of British Columbia. Dr. Thomas is currently a dermatologist at Sidra Hospital and Research Centre for Women and Children in Doha,

Qatar. He has over two decades of experience in dermatology including dermatological clinical trials, various dermatology society memberships, and an active practice and laser dermatology clinic. Dr. Thomas has a visionary approach to the internet and dermatology and is a leader in melding the information needs of physicians and consumers via internet technologies. While he was the president of the British Columbia Medical Association Section of Dermatology, Dr Thomas founded the Dermatology Society of British Columbia. He has served as a British Columbia representative on the board of directors of the Canadian Dermatology Association. He is currently the Managing Editor of Skin Therapy Letter, a peer-reviewed journal, indexed with the National Library in Washington and distributed to over 29,000 dermatologists worldwide.

Jeffrey S. Dover, M.D., FRCPC: Dr. Dover is a former Associate Professor of Dermatology at Harvard Medical School, was Chief of Dermatology at the New England Deaconess Hospital for over ten years and also Associate Chairman of Dermatology at Beth Israel Deaconess Medical Center. He is Associate Clinical Professor of Dermatology at Yale University School of Medicine and Adjunct Associate Professor of Dermatology at Brown Medical School. He is co-director of SkinCare Physicians of Chestnut Hill, one of America's preeminent dermatology practices. Dr. Dover has received many honors including listings in the *Who's Who of American Medicine*, *Who's Who in America*, *Guide to Top Doctors*, *Woodward and White's The Best Doctors in America*, in multiple editions of Boston Magazine's Boston Top Docs, and repeated nominations for the Teacher of The Year Award at Harvard Medical School. Dr. Dover is the author of over 450 scientific publications.

Leon Kircik, MD, FAAD: Dr. Kircik is the Medical Director of DermResearch, PLLC and Physicians Skin Care, PLLC in Louisville, Kentucky, as well as Associate Clinical Professor of Dermatology at Indiana University Medical Center and Icahn School of Medicine at Mount Sinai Medical Center. He has been the principal investigator of clinical trials for conditions including psoriasis, acne, rosacea and atopic dermatitis. Dr. Kircik is an author of many scientific articles,

abstracts and posters. He has lectured extensively both nationally and internationally on all aspects of dermatologic conditions. In addition, he also serves on the advisory boards of several pharmaceutical companies as a consultant. He is on the editorial board of Journal of Drugs in Dermatology, Practical Dermatology, The Journal of Clinical & Aesthetic Dermatology, and Case Report in Clinical Pathology. He volunteers for multiple local and national medical society committees.

About Ovation Science Inc.

Ovation Science Inc. is a research and development company that develops topical and transdermal cannabis and hemp formulations made with patented Invisicare® skin delivery technology. The technology enhances the delivery of cannabidiol (CBD) and tetrahydrocannabinol (THC) to and through the skin and is protected by patents in eleven countries. With over twenty years of topical and transdermal drug delivery experience in the pharmaceutical market, Ovation's management and science team have created a unique pipeline of over twenty-five patent-protected medical / wellness topical and transdermal cannabis products incorporating CBD, THC and combination products along with a line of anti-aging / beauty products made with CBD. Ovation's business model is to develop, market as well as license-out its topical and transdermal formulations to cannabis companies globally. Ovation earns revenues from licensing and development fees, royalties, the sale of Invisicare to its licensees and now revenue from its own product sales. Ovation trades on the CSE under the symbol OVAT. Visit our website www.ovationscience.com.

Forward-Looking Statements

Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. Ovation Science Inc. cautions that all forward looking statements are inherently uncertain and that actual results may be affected by a number of material factors, many of which are beyond Ovation Science Inc.'s control.

Neither the Canadian Securities Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.

SOURCE Ovation Science Inc.

View original content to download multimedia:

<http://www.newswire.ca/en/releases/archive/April2019/23/c1883.html>

%SEDAR: 00045501E

For further information: FOR INVESTOR RELATIONS: Dave Ryan, ir@ovationscience.com, Phone: 604-283-0903 ext. 2; FOR BUSINESS DEVELOPMENT & CORPORATE INQUIRIES: Doreen McMorran, doreen@ovationscience.com, Phone: 604.283.0903 ext. 4

CO: Ovation Science Inc.

CNW 09:00e 23-APR-19